转移性肾细胞癌的新方案：SOG-GU 共识。
A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus.
机构信息
Medical Oncology Department, Hospital Universitario Lucus Augusti (Lugo), Dr. Ulises Romero, s/n, 27003, Lugo, Spain.
Medical Oncology Department, Complejo Hospitalario Universitario Santiago de Compostela, Trav. da Choupana, s/n, 15702, Santiago de Compostela, Spain.
出版信息
Clin Transl Oncol. 2020 Sep;22(9):1565-1579. doi: 10.1007/s12094-020-02300-2. Epub 2020 Feb 15.
BACKGROUND
This article describes and compares approved targeted therapies and the newer immunotherapy agents.
MATERIALS AND METHODS
This article especially performs an in-depth review of currently available data for tivozanib, explaining its mechanism of action, its safety profile and its role as an efficacy drug in the management of renal cancer.
RESULTS
Despite the fact that the treatment of advanced RCC has been dramatically modified in recent years, durable remissions are scarce and it remains a lethal disease. For first- and second-line therapy, there is now growing evidence to guide the selection of the appropriate treatment.
CONCLUSIONS
Several TKIs are standard of care at different settings. Among those approved TKIs, tivozanib has similar efficacy than others with a better safety profile. The use of prognostic factors is critical to the selection of optimal therapy.
背景
本文描述并比较了已批准的靶向治疗药物和较新的免疫治疗药物。
材料与方法
本文特别深入地回顾了替沃扎尼的现有数据，解释了其作用机制、安全性概况及其在肾癌治疗中的疗效药物作用。
结果
尽管近年来晚期 RCC 的治疗已经发生了重大变化，但持久缓解仍然很少见，而且仍然是一种致命的疾病。对于一线和二线治疗，现在有越来越多的证据可以指导选择适当的治疗方法。
结论
几种 TKI 在不同情况下都是标准治疗方法。在已批准的 TKI 中，替沃扎尼的疗效与其他药物相当，但其安全性更好。预后因素的使用对选择最佳治疗方法至关重要。
Zotero 插件